![konica minolta precision medicine konica minolta precision medicine](https://medicalimagingmarketcom.files.wordpress.com/2020/02/konica-minolta-himss-2019.jpg)
![konica minolta precision medicine konica minolta precision medicine](https://www.konicaminolta.com/newsroom/img/default_thumbnail_1_2_top.jpg)
Further, Invicro will continue to invest in its data informatics platforms, enabling management, visualization, and analysis of pathological and radiological imaging data and ensuring alignment with KMPM. Invicro will continue to leverage its industry-leading imaging, chemistry, and analysis expertise that span discovery through clinical research across multiple therapeutic areas, including the central nervous system, oncology, rare disease, and other systemic diseases. Silva will carry on Invicro’s strategic mission to support the drug discovery and development community.
![konica minolta precision medicine konica minolta precision medicine](https://realmidx.com/wp-content/uploads/2021/09/featured.jpg)
#Konica minolta precision medicine full#
I have full confidence that Matt will seamlessly transition to his new role and continue to lead Invicro into new breakthroughs that will help advance the discovery and development of life-changing medicines.”ĭr. “As KMPM continues to focus on revolutionizing personalized healthcare via the strengths of Konica Minolta, Invicro and Ambry, Jack will be instrumental in leading and realizing the Konica Minolta Precision Medicine mission. Kiyotaka Fujii, president of Konica Minolta Global Healthcare and CEO of KMPM. “I’m looking forward to seeing the next chapter for KMPM and Invicro,” said Mr. Hoppin will work to synergize the companies under KMPM to help pharmaceutical sponsors and clinicians accelerate the development of targeted therapies through genetic and molecular profiling. “This is an exciting time for Invicro, Ambry and KMPM, as we are all working together to support the medical research community through integrated AI technology platforms that allow molecular-level testing and analysis offering insights to advance translational medicine.” “It has been an extreme honor to serve as Invicro’s CEO, since co-founding the company in 2008,” stated Dr. Konica Minolta Precision Medicine was formalized as a result of bringing these three entities together. acquired Invicro LLC and Ambry Genetics Corporation in September 2017 to accelerate its strategic vision to transform personalized medicine through the delivery of diagnostic services via genetics, imaging and digital pathology capabilities. Hoppin will remain on Invicro’s Board of Directors, as well as continue to serve on the KMPM Board. Jack Hoppin, co-founder of Invicro, will move on from his role as Invicro’s CEO to be the President of Konica Minolta Precision Medicine (KMPM). Silva will assume the day-to-day leadership responsibilities of the Company and will join Invicro’s Board of Directors, effective immediately. Matthew Silva has been appointed as the new Chief Executive Officer. “Our CARE for COVID Program will soon incorporate a portfolio of testing options providing businesses a full view of the landscape of employee health to help ensure that everyone is as safe as possible in the face of the ongoing pandemic,” Chief Commercial Officer of Ambry, Tom Shoenherr concluded in his statement.BOSTON-(Antara/BUSINESS WIRE)- Invicro LLC, a Konica Minolta company, today announces, Dr. “We can tailor our CARE for COVID Program to meet employers’ individual needs as employees return to work and to support continued employee health and wellness,” Aaron Elliott further said.Ĭhief Commercial Officer of Ambry, Tom Shoenherr said, “We recognize that every business has its own specific needs and concerns as they open up again and that a best-in-class screening and testing program would have to be flexible enough to fit any organization.” The CARE platform is that turn-key solution from screening to testing that helps provide a safe work environment and a limited potential exposure.” The AI-based virtual model helps the employees to rapidly share the screening results from the mobile phones, tablets and computers to assess the risk of returning to work.Ĭhief Executive Officer of Ambry, Aaron Elliott said, “To aid in employee safety, return-to-work initiatives, and general peace of mind, employers need a clinically validated, comprehensive, and cost-effective approach. The company’s solution will offer the saliva RT-PCR test to determine the active COVID-19 infection in patients. The Konica Minolta Precision’s launched CARE for COVID significantly helped the employees to test and scan their employees based on the latest guidelines and SOP’s provided by the Centre for Disease Control. Konica Minolta Precision that the company has launched the CARE of COVID program to help employers with the tools, systems and support they need to test, scan and manage their employees as they return to work.